These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 31060225)

  • 21. Dynamic Changes in PD-L1 Expression and Immune Infiltrates Early During Treatment Predict Response to PD-1 Blockade in Melanoma.
    Vilain RE; Menzies AM; Wilmott JS; Kakavand H; Madore J; Guminski A; Liniker E; Kong BY; Cooper AJ; Howle JR; Saw RPM; Jakrot V; Lo S; Thompson JF; Carlino MS; Kefford RF; Long GV; Scolyer RA
    Clin Cancer Res; 2017 Sep; 23(17):5024-5033. PubMed ID: 28512174
    [No Abstract]   [Full Text] [Related]  

  • 22. Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.
    Brogden KA; Parashar D; Hallier AR; Braun T; Qian F; Rizvi NA; Bossler AD; Milhem MM; Chan TA; Abbasi T; Vali S
    BMC Cancer; 2018 Feb; 18(1):225. PubMed ID: 29486723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.
    Zabeti Touchaei A; Vahidi S
    Cancer Cell Int; 2024 Mar; 24(1):102. PubMed ID: 38462628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blocking TGF-β Signaling To Enhance The Efficacy Of Immune Checkpoint Inhibitor.
    Bai X; Yi M; Jiao Y; Chu Q; Wu K
    Onco Targets Ther; 2019; 12():9527-9538. PubMed ID: 31807028
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges.
    Macek Jilkova Z; Aspord C; Decaens T
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31615069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
    Larsen TV; Hussmann D; Nielsen AL
    Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond.
    Buder-Bakhaya K; Hassel JC
    Front Immunol; 2018; 9():1474. PubMed ID: 30002656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Programmed Cell Death Protein 1 (PD-1) and Programmed Cell Death Ligand 1 (PD-L1) Immunotherapy: A Promising Breakthrough in Cancer Therapeutics.
    Abaza A; Sid Idris F; Anis Shaikh H; Vahora I; Moparthi KP; Al Rushaidi MT; Muddam MR; Obajeun OA; Jaramillo AP; Khan S
    Cureus; 2023 Sep; 15(9):e44582. PubMed ID: 37667784
    [TBL] [Abstract][Full Text] [Related]  

  • 30. First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress.
    Huang Z; Su W; Lu T; Wang Y; Dong Y; Qin Y; Liu D; Sun L; Jiao W
    Front Pharmacol; 2020; 11():578091. PubMed ID: 33117170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer - A systematic review and network meta-analysis of 3024 participants.
    Tan PS; Aguiar P; Haaland B; Lopes G
    Lung Cancer; 2018 Jan; 115():84-88. PubMed ID: 29290267
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer.
    Hsu PC; Yang CT; Jablons DM; You L
    Biomedicines; 2018 Dec; 6(4):. PubMed ID: 30544524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A snapshot of the PD-1/PD-L1 pathway.
    Ghosh C; Luong G; Sun Y
    J Cancer; 2021; 12(9):2735-2746. PubMed ID: 33854633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
    Takahashi T; Tateishi A; Bychkov A; Fukuoka J
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31130676
    [TBL] [Abstract][Full Text] [Related]  

  • 36. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
    Hays E; Bonavida B
    Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer.
    Gong X; Li X; Jiang T; Xie H; Zhu Z; Zhou F; Zhou C
    J Thorac Oncol; 2017 Jul; 12(7):1085-1097. PubMed ID: 28478231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
    Gibbons Johnson RM; Dong H
    Front Immunol; 2017; 8():961. PubMed ID: 28848559
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
    Sato R; Imamura K; Sakata S; Ikeda T; Horio Y; Iyama S; Akaike K; Hamada S; Jodai T; Nakashima K; Ishizuka S; Sato N; Saruwatari K; Saeki S; Tomita Y; Sakagami T
    J Clin Med; 2019 May; 8(6):. PubMed ID: 31146442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
    Kluger HM; Zito CR; Turcu G; Baine MK; Zhang H; Adeniran A; Sznol M; Rimm DL; Kluger Y; Chen L; Cohen JV; Jilaveanu LB
    Clin Cancer Res; 2017 Aug; 23(15):4270-4279. PubMed ID: 28223273
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.